Literature DB >> 568479

A sensitive test demonstrating lupus anticoagulant and its behavioural patterns.

T Exner, K A Rickard, H Kronenberg.   

Abstract

The kaolin clotting time of platelet poor plasma was used as a sensitive test for detecting the lupus anticoagulant in mixtures of normal and patients' plasmas. Platelets were found to decrease the anticoagulant effect of a typical lupus inhibitor. Thus, high sensitivity in this test system was achieved by ensuring low platelet concentrations and omitting platelet lipid substitute. In 17 patients with disseminated lupus erythematosus (DLE), 12 had detectable inhibitor by this method, more than would be detected with routine coagulation tests. Mixing patterns were of four distinct types, representing three different modes of anticoagulant behaviour. The pattern (type 3) of plasma mixtures giving longer kaolin clotting times than the individual components could be reproduced in vitro by adding trace amounts of crude thrombin or platelet fragments to a more typical lupus anticoagulant-containing plasma; formation of such a mixing pattern by the plasma of a patient with DLE may therefore indicate activation of the coagulation pathway. Six patients with idopathic thrombocytopenic purpura (ITP) had no detectable inhibitor indicating that anti-platelet antibodies behave differently from the lupus anticoagulant.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 568479     DOI: 10.1111/j.1365-2141.1978.tb03648.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  42 in total

1.  Anticardiolipin antibodies and renovascular hypertension.

Authors:  E Rossi; C Sani; M Zini; M C Casoli; G Restori
Journal:  Ann Rheum Dis       Date:  1992-10       Impact factor: 19.103

2.  Detection of lupus like anticoagulant: current laboratory practice in the United Kingdom. The Lupus Anticoagulant Working Party.

Authors: 
Journal:  J Clin Pathol       Date:  1990-01       Impact factor: 3.411

Review 3.  Influence of the lupus anticoagulant on clotting tests.

Authors:  J Vermylen; J Arnout
Journal:  Clin Rheumatol       Date:  1990-03       Impact factor: 2.980

4.  Anticardiolipin antibodies in patients with chronic hepatitis C virus infection: characterization in relation to antiphospholipid syndrome.

Authors:  J Ordi-Ros; J Villarreal; F Monegal; S Sauleda; I Esteban; M Vilardell
Journal:  Clin Diagn Lab Immunol       Date:  2000-03

5.  Acquired factor XI inhibitor in chronic lymphocytic leukaemia.

Authors:  M J Goodrick; A G Prentice; J A Copplestone; D H Pamphilon; R J Boon
Journal:  J Clin Pathol       Date:  1992-04       Impact factor: 3.411

6.  Species specificity of lupus-like anticoagulants.

Authors:  L P Clyne
Journal:  Blut       Date:  1986-10

7.  Presence of lupus anticoagulant in an asymptomatic Nigerian.

Authors:  Edeghonghon E Olayemi; Godwin N Bazuaye
Journal:  Afr Health Sci       Date:  2007-09       Impact factor: 0.927

8.  Guidelines on testing for the lupus anticoagulant. Lupus Anticoagulant Working Party on behalf of the BCSH Haemostasis and Thrombosis Task Force.

Authors: 
Journal:  J Clin Pathol       Date:  1991-11       Impact factor: 3.411

9.  Lupus anticoagulant: clinical significance in anticardiolipin positive patients with systemic lupus erythematosus.

Authors:  N J McHugh; D A Moye; I E James; M Sampson; P J Maddison
Journal:  Ann Rheum Dis       Date:  1991-08       Impact factor: 19.103

10.  Monoclonal anticardiolipin antibodies derived from mice with experimental lupus erythematosus: characterization and the induction of a secondary antiphospholipid syndrome.

Authors:  Z M Sthoeger; B Tartakovsky; Z Bentwich; E Mozes
Journal:  J Clin Immunol       Date:  1993-03       Impact factor: 8.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.